Aiforia, a developer of AI-powered solutions for cancer diagnostics, has won the prestigious “Vuoden Digiteko 2026” (Digital Innovation of the Year) public vote in the enterprise category. The “Vuoden Digiteko” competition rewards Finnish technology innovations and solutions that have an exceptionally high impact on society, business, and people’s everyday lives. The winners of the competition were announced yesterday at the Atea Focus event at Helsinki Expo and Convention Centre.

The jury of the competition justified the selection of Aiforia as a finalist in the competition as follows:

“The solution transforms the workflow of pathologists and revolutionizes diagnostics. This enables faster treatment, which is why the solution has major societal significance. Aiforia® Create enhances precision and patient equality. Innovation is no longer experimental, but widely used, with credibility brought in particular by the Mayo Clinic in the US. The solution has a lot of international potential. From a technology perspective, the solution is fantastic.”

Pathology is the cornerstone of cancer treatment and diagnostics, but the industry suffers from a global shortage of resources while the number of samples is growing. Aiforia has developed a software solution that helps pathologists identify cancer from tissue sample images more accurately using AI. This not only streamlines the work of pathologists, but also ensures a more consistent, accurate, and rapid diagnosis for patients regardless of their place of residence.

“We are extremely pleased with this recognition. This win is a great demonstration of our team’s dedication and the high standard of Finnish health tech. We remain ambitious in the ongoing development of our solutions, as our goal is to make AI-assisted diagnostics the new global standard,” says Jukka Tapaninen, CEO of Aiforia.

About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.

Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.